Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by EyePoint, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335037
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 507 | 5,333 | 1,203 | 29,786 |
| Operating expenses: | ||||
| Cost of sales | — | 165 | 533 | 970 |
| Research and development | 83,614 | 55,498 | 155,757 | 114,072 |
| Sales and marketing | 31 | 35 | 34 | 70 |
| General and administrative | 14,242 | 11,862 | 29,485 | 25,738 |
| Total operating expenses | 97,887 | 67,560 | 185,809 | 140,850 |
| Loss from operations | (97,380) | (62,227) | (184,606) | (111,064) |
Item 1. Unaudited Financial Statements
FAQ
- What is EyePoint, Inc.'s R&D?
- EyePoint, Inc. (EYPT) reported R&D of $83.61M in Q2 2026.
- How has EyePoint, Inc.'s R&D changed year-over-year?
- EyePoint, Inc.'s R&D increased by 50.7% year-over-year, from $55.5M to $83.61M.
- What is the long-term trend for EyePoint, Inc.'s R&D?
- Over 4 years (2021 to 2025), EyePoint, Inc.'s R&D has grown at a 66.9% compound annual growth rate (CAGR), from $28.5M to $221.04M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about EyePoint, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude